+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes



Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes



Biochimica et Biophysica Acta 1820(5): 663-671



A non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules, whose process has been known to progress at an accelerated rate under hyperglycemic and/or oxidative stress conditions. Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent protein derivatives termed advanced glycation end products (AGEs). In this paper, we review the role of AGE-oxidative stress axis and its therapeutic interventions in vascular complications in diabetes. AGEs elicit oxidative stress generation and subsequently cause inflammatory and thrombogenic reactions in various types of cells via interaction with a receptor for AGEs (RAGE), thereby being involved in vascular complications in diabetes. In addition, mitochondrial superoxide generation has been shown to play an important role in the formation and accumulation of AGEs under diabetic conditions. Further, we have recently found that a pathophysiological crosstalk between AGE-RAGE axis and renin-angiotensin system (RAS) could contribute to the progression of vascular damage in diabetes. These observations suggest that inhibition of AGE-RAGE-oxidative stress axis or blockade of its interaction with RAS is a novel therapeutic strategy for preventing vascular complications in diabetes.

(PDF emailed within 0-6 h: $19.90)

Accession: 055600552

Download citation: RISBibTeXText

PMID: 21440603

DOI: 10.1016/j.bbagen.2011.03.014


Related references

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental Gerontology 46(4): 217-224, 2011

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Current Pharmaceutical Design 14(10): 962-968, 2008

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Therapeutic Apheresis and Dialysis 13(6): 534-539, 2010

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17(7): 983-996, 2008

Oxidative stress in diabetes - circulating advanced glycation end products, lipid oxidation and vascular disease. Annals of Clinical Biochemistry 51(Pt 2): 125-127, 2014

Role of advanced glycation end products (AGE) and soluble receptor for AGE (sRAGE) in vascular complications in diabetes. Nihon Rinsho. Japanese Journal of Clinical Medicine 70 Suppl 5: 243-247, 2013

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrology, Dialysis, Transplantation 11 Suppl 5: 13-16, 1996

A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clinical Biochemistry 46(1-2): 109-114, 2013

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Possible role of HMG CoA reductase inhibitor on the oxidative stress induced by advanced glycation endproducts(AGEs) in vascular smooth muscle cell(VSMC) of diabetic vasculopathy. 2007

Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Current Pharmaceutical Biotechnology 12(3): 362-368, 2011

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chinese Journal of Natural Medicines 14(11): 844-855, 2017

New metabolic marker: Advanced glycation end products (AGEs) and receptor for advanced glycation end products (RAGE) system may play a role in the pathogenesis of recurrent pregnancy losses. Journal of Reproductive Immunology 106: 10-11, 2014

Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Current Drug Targets 12(14): 2096-2102, 2012